Stockreport

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncolo...

Celcuity Inc.  (CELC) 
Last celcuity inc. earnings: 3/12 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: celcuity.com/home/investors
PDF As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of diseas [Read more]